Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment

NCT ID: NCT02381782

Last Updated: 2018-02-15

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 33 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2015-06-30

Brief Summary

Over the last few years, there has been a considerable interest in the development of screening tools to assess the capability of elderly cancer patients to tolerate anti-cancer treatment. Therefore, the NCCN Guidelines in Senior Adult Oncology recommend an assessment of co-morbid conditions that are likely to interfere with cancer treatment and tolerability. As presbyacusis is common in an older population, elderly cancer patients are at high risk for social isolation and a reduced quality of life. Therefore, in this project the investigators aim to validatie uHear™ as a quick and reliable screening tool to screen for presbyacusisf in routine clinical oncology practice.

Conditions

Hearing Loss; Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Patients should have reached the age of 70 or more at enrolment
• Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible
• Patients should be fluent in Dutch or French
• Patients must receive their primary oncology care in the participating hospital
• Patients should be cognitively capable of performing the audiology assessment
• Patients should have signed informed consent

• Patients who are visiting the oncology clinic for a second opinion and do not wish to be treated in this clinic
• Patients presenting with clinically diagnosed Ménière's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss
• Patients who already have a hearing aid or a previously diagnosed hearing loss

• Minimum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

General Hospital Groeninge

OTHER

Sponsor Role: lead

Responsible Party

Dr. Philip Debruyne

Medical Oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Philip R Debruyne, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Cancer Center, General Hospital Groeninge

Locations

General Hospital Groeninge

Kortrijk, , Belgium

Countries

Belgium

References

Lycke M, Boterberg T, Martens E, Ketelaars L, Pottel H, Lambrecht A, Van Eygen K, De Coster L, Dhooge I, Wildiers H, Debruyne PR. Implementation of uHear--an iOS-based application to screen for hearing loss--in older patients with cancer undergoing a comprehensive geriatric assessment. J Geriatr Oncol. 2016 Mar;7(2):126-33. doi: 10.1016/j.jgo.2016.01.008. Epub 2016 Feb 26.

Reference Type: RESULT

PMID: 26924571 (View on PubMed)

Other Identifiers

AZGS2014125

Identifier Type: -

Identifier Source: org_study_id